| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
Malignant peripheral nerve sheath tumor (MPNST) is a histologic subtype of soft tissue sarcoma. Patients with advanced soft tissue sarcoma including MPNST have poor prognosis and no effective therapeutic drugs, so that development of novel therapeutic drugs is awaited. We have found that depsipeptide analogs inhibit cancer cell proliferation with a mechanism of dual inhibition of HDAC and PI3K, both of which are regarded as molecular targets for soft tissue sarcoma therapy. In this study, the effects of depsipeptide analogs were evaluated using MPNST cell lines and a fibrosarcoma cell line. Because the proliferation rate of MPNST cells was slow and it was difficult to establish an experimental system by a mouse model, experiments were carried out using a fibrosarcoma cell line. We showed antitumor effect and the mechanism of action of HDAC/PI3K dual inhibition of the depsipeptide analog in fibrosarcoma tumor tissue.
|
